[go: up one dir, main page]

TW200616977A - Enantiomers of selected fused heterocyclics and uses thereof - Google Patents

Enantiomers of selected fused heterocyclics and uses thereof

Info

Publication number
TW200616977A
TW200616977A TW094128220A TW94128220A TW200616977A TW 200616977 A TW200616977 A TW 200616977A TW 094128220 A TW094128220 A TW 094128220A TW 94128220 A TW94128220 A TW 94128220A TW 200616977 A TW200616977 A TW 200616977A
Authority
TW
Taiwan
Prior art keywords
enantiomers
selected fused
fused heterocyclics
heterocyclics
novel compounds
Prior art date
Application number
TW094128220A
Other languages
English (en)
Inventor
Brian Aquila
Michael Howard Block
Audrey Davies
Jayachandran Ezhuthachan
Timothy Pontz
Daniel John Russell
Marie-Elena Theoclitou
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37904998&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200616977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TW200616977A publication Critical patent/TW200616977A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
TW094128220A 2004-08-18 2005-08-18 Enantiomers of selected fused heterocyclics and uses thereof TW200616977A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60236604P 2004-08-18 2004-08-18

Publications (1)

Publication Number Publication Date
TW200616977A true TW200616977A (en) 2006-06-01

Family

ID=37904998

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094128220A TW200616977A (en) 2004-08-18 2005-08-18 Enantiomers of selected fused heterocyclics and uses thereof

Country Status (18)

Country Link
US (3) US20080293744A1 (zh)
EP (1) EP1781674A1 (zh)
JP (1) JP2008509977A (zh)
KR (1) KR20070046176A (zh)
CN (1) CN101027309B (zh)
AU (1) AU2005273705B8 (zh)
BR (1) BRPI0514390A (zh)
CA (1) CA2575188A1 (zh)
IL (1) IL180810A0 (zh)
MX (1) MX2007001953A (zh)
MY (1) MY141233A (zh)
NO (1) NO20071005L (zh)
RU (1) RU2447077C2 (zh)
SA (1) SA05260258B1 (zh)
TW (1) TW200616977A (zh)
UA (1) UA89201C2 (zh)
UY (1) UY29070A1 (zh)
ZA (1) ZA200701082B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008321099A1 (en) * 2007-11-13 2009-05-22 Icos Corporation Inhibitors of human phosphatidyl-inositol 3-kinase delta
MX2011013816A (es) 2009-06-29 2012-04-11 Incyte Corp Pirimidinonas como inhibidores de pi3k.
KR20230038593A (ko) 2011-09-02 2023-03-20 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
PE20180129A1 (es) 2015-02-27 2018-01-18 Incyte Corp Sales de inhibidor de pi3k y procesos de preparacion
HK1261923A1 (zh) 2015-09-14 2020-01-10 Twelve Therapeutics, Inc. 异喹啉酮衍生物的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2024103067A1 (en) * 2022-11-10 2024-05-16 Ribometrix, Inc. COMPOUNDS AND COMPOSITIONS AS eIF4E INHIBITORS AND USES THEREOF

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
AU716248B2 (en) 1996-03-11 2000-02-24 Novartis Ag Pyrimidin-4-one derivatives as pesticide
WO2000039131A1 (en) 1998-12-23 2000-07-06 Du Pont Pharmaceuticals Company Nitrogen containing heterobicycles as factor xa inhibitors
AU780846B2 (en) 1999-09-16 2005-04-21 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
MXPA02004162A (es) 1999-10-27 2003-08-20 Cytokinetics Inc Metodo y composiciones que utilizan quinazolinonas.
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002083143A1 (en) 2000-12-11 2002-10-24 Tularik Inc. Cxcr3 antagonists
US6809102B2 (en) 2001-03-29 2004-10-26 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2442455A1 (en) 2001-03-29 2002-10-10 Deborah L. Roussell A method of treating proliferative diseases using eg5 inhibitors
AU2002305205A1 (en) 2001-04-20 2002-11-05 Jingrong Cao 9-deazaguanine derivatives as inhibitors of gsk-3
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003043995A1 (en) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
JP2005515208A (ja) * 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
CA2468156A1 (en) * 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
ES2291543T3 (es) 2001-12-06 2008-03-01 MERCK & CO., INC. Inhibicion de kinesina mitotica.
US20050107404A1 (en) * 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
EP1458726B1 (en) * 2001-12-06 2009-07-15 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
PL211300B1 (pl) 2002-04-17 2012-05-31 Cytokinetics Inc Związek i kompozycja zawierająca ten związek
MXPA04011074A (es) 2002-05-09 2005-06-08 Cytokinetics Inc Compuestos de pirimidinona, composiciones y metodos.
WO2003097053A1 (en) 2002-05-09 2003-11-27 Cytokinetics, Inc. Compounds, compositions, and methods
TW200407143A (en) 2002-05-21 2004-05-16 Bristol Myers Squibb Co Pyrrolotriazinone compounds and their use to treat diseases
CA2483627A1 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005536475A (ja) 2002-05-23 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物、および方法
WO2004039774A2 (en) 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
AU2003236527A1 (en) 2002-06-14 2003-12-31 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003252025A1 (en) 2002-07-17 2004-02-02 Cytokinetics, Inc. Compounds, compositions, and methods
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
JP2005536553A (ja) 2002-08-21 2005-12-02 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
EP1554265A4 (en) 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
AU2003277079A1 (en) 2002-09-30 2004-05-04 Cytokinetics, Inc. Compounds, compositions, and methods
EP1558589A4 (en) 2002-10-11 2008-01-09 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
RU2005114491A (ru) 2002-10-11 2006-02-10 Цитокинетикс, Инк. (Us) Соединения, составы и способы их использования
WO2004064741A2 (en) 2003-01-17 2004-08-05 Cytokinetics Inc. Compounds, compositions, and methods
JP3947758B2 (ja) * 2003-03-07 2007-07-25 アストラゼネカ アクチボラグ 新規縮合ヘテロサイクル及びその使用
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
EP1622883A4 (en) 2003-04-10 2008-04-02 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
JP2007500213A (ja) 2003-05-07 2007-01-11 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005013888A2 (en) 2003-05-14 2005-02-17 Cytokinetics, Inc. Compounds, compositions and methods
US20070032536A1 (en) 2003-05-15 2007-02-08 Xianping Qian Compounds, compositions and methods
US7022850B2 (en) * 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en) * 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
CN1809563A (zh) 2003-06-20 2006-07-26 希龙公司 吡啶并[1,2－a]嘧啶－4－酮化合物用作抗癌药
US20050165089A1 (en) * 2003-10-06 2005-07-28 Gustave Bergnes Compounds, compositions and methods
WO2005046588A2 (en) 2003-11-07 2005-05-26 Cytokinetics, Inc. Compounds, compositions, and methods
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
CA2546932A1 (en) 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
JP2007513154A (ja) 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
US7501416B2 (en) * 2004-02-06 2009-03-10 Bristol-Myers Squibb Company Quinoxaline compounds and methods of using them
US7504405B2 (en) * 2004-04-06 2009-03-17 Novartis Vaccines And Diagnostics, Inc. Mitotic kinesin inhibitors
BRPI0511433A (pt) 2004-05-21 2007-12-11 Chiron Corp derivados de quinolina substituìda como inibidores de cinesina mitótica
CN1993331A (zh) 2004-06-18 2007-07-04 希龙公司 N－(1－(1－苄基－4－苯基－1h－咪唑－2－基 )－2 , 2－二甲基丙基)苯甲酰胺衍生物和相关化合物作为用于治疗癌症的驱动蛋白纺锤蛋白(ksp)抑制剂
DE602005017283D1 (de) 2004-08-18 2009-12-03 Astrazeneca Ab Ausgewählte kondensierte heterocyclen und deren anwendung
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
RU2007118523A (ru) * 2004-10-19 2008-11-27 Новартис Вэксинс Энд Диагностикс Инк. (Us) Производные индола и бензимидазола

Also Published As

Publication number Publication date
US20060041129A1 (en) 2006-02-23
AU2005273705B2 (en) 2009-12-10
RU2447077C2 (ru) 2012-04-10
EP1781674A1 (en) 2007-05-09
RU2007109866A (ru) 2008-09-27
US7498333B2 (en) 2009-03-03
AU2005273705B8 (en) 2010-01-28
SA05260258B1 (ar) 2009-12-22
UA89201C2 (ru) 2010-01-11
US20080293744A1 (en) 2008-11-27
UY29070A1 (es) 2006-03-31
CN101027309B (zh) 2010-10-27
MX2007001953A (es) 2007-05-09
KR20070046176A (ko) 2007-05-02
ZA200701082B (en) 2008-07-30
US20090099210A1 (en) 2009-04-16
JP2008509977A (ja) 2008-04-03
CN101027309A (zh) 2007-08-29
AU2005273705A1 (en) 2006-02-23
CA2575188A1 (en) 2006-02-23
NO20071005L (no) 2007-05-16
IL180810A0 (en) 2007-06-03
MY141233A (en) 2010-03-31
BRPI0514390A (pt) 2008-06-10

Similar Documents

Publication Publication Date Title
TW200716606A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
TW200800963A (en) Chemical compounds
PT1853588E (pt) Compostos químicos
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
MXPA05009885A (es) Nuevas triazolonas fusionadas y los usos de las mismas.
TW200738659A (en) Novel compounds
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
TW200800999A (en) Novel compounds
TW200801003A (en) Novel compounds
UA94833C2 (en) Substituted bicyclolactams
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
TW200700064A (en) Novel compounds
TW200745084A (en) Novel compounds
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200639156A (en) New compounds
TW200510427A (en) Novel fused heterocycles and uses thereof
TW200616977A (en) Enantiomers of selected fused heterocyclics and uses thereof
ATE419242T1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
TW200621260A (en) Selected fused heterocyclics and uses thereof
ATE542796T1 (de) N-sulfonylcarboximidamidverbindungen als apoptosepromotoren
MX2008007195A (es) Inhibidores de proteasas de cisteina, composiciones farmaceuticas de las mismas y sus aplicaciones terapeuticas.